Test Home2021-06-07T10:17:32+02:00

The Psyence™ Group sets the global standard for natural psychedelics.

Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.

We are focused on the development of psilocybin medical products for research institutions and clinics and will also manufacture regulatory-compliant over the counter psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.

The Psyence™ Group sets the global standard for natural psychedelics.

Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.

We are focused on the development of psilocybin medical products for research institutions and clinics and will also manufacture regulatory-compliant over the counter psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.

Psyence is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.

[layerslider id=”2″ /]

Bringing together leaders in the business of medicine and science

Our scientific and medical team, which includes experts in neurology, neuroscience, oncology and drug development, have international expertise in palliative medicine and science. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.

THerapuetics_Logo 400pxwide

We develop natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment.

production_Logo 400pxwide

We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world.

Psyece Funcitonblue 400px

With experience in building disruptive brands and creating routes to market, we are focused on the development of over-the-counter proprietary nutraceutical products.

Psyence_Logo 400pxwide

We will partner with experienced providers of retreats and clinics in legal jurisdictions to inform our medical and product development strategy.

Our News

  • With Appointment of Dr. Dan J. Stein

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

March 26, 2025|

Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it has expanded its newly created Scientific Advisory Board (SAB) with the addition of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology.

  • Scientific Advisory Board_1

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

March 11, 2025|

Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB).

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

December 7, 2024|

Psyence Group hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the "Debt Swap Agreements") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 337,750 Psyence Biomed common shares at a deemed price of US$3.88 per common share, in exchange for the discharging of the balance of Psyence Biomed's obligations due under the Debt Swap Agreements and a promissory note, dated January 25, 2024, issued by Psyence Biomed to the Company in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024.

Our Global Footprint

Our team and operations are located across Toronto, Canada; Washington DC, United States of America; Cape Town, South Africa; Kolojane, Kingdom of Lesotho; Kingston, Jamaica; London United Kingdom; Sydney, Australia and Sao Paulo, Brazil.

Our News

  • With Appointment of Dr. Dan J. Stein

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

March 26, 2025|

Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it has expanded its newly created Scientific Advisory Board (SAB) with the addition of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology.

  • Scientific Advisory Board_1

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

March 11, 2025|

Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB).

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

December 7, 2024|

Psyence Group hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the "Debt Swap Agreements") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 337,750 Psyence Biomed common shares at a deemed price of US$3.88 per common share, in exchange for the discharging of the balance of Psyence Biomed's obligations due under the Debt Swap Agreements and a promissory note, dated January 25, 2024, issued by Psyence Biomed to the Company in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024.

Our Global Footprint

Our team and operations are located across Toronto, Canada; Washington DC, United States of America; Cape Town, South Africa; Kolojane, Kingdom of Lesotho; Kingston, Jamaica; London United Kingdom; Sydney, Australia and Sao Paulo, Brazil.

Go to Top